Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy
SN38 (7-ethyl-10-hydroxy camptothecin) is a potent anticancer agent belonging to the camptothecin family; however, its oral delivery is extensively restricted by poor solubility in pharmaceutically acceptable excipients and low transmucosal permeability. Lipid-based carriers are well-known for their...
Saved in:
Published in | Molecular pharmaceutics Vol. 13; no. 1; pp. 287 - 294 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
04.01.2016
|
Subjects | |
Online Access | Get full text |
ISSN | 1543-8384 1543-8392 |
DOI | 10.1021/acs.molpharmaceut.5b00785 |
Cover
Abstract | SN38 (7-ethyl-10-hydroxy camptothecin) is a potent anticancer agent belonging to the camptothecin family; however, its oral delivery is extensively restricted by poor solubility in pharmaceutically acceptable excipients and low transmucosal permeability. Lipid-based carriers are well-known for their ability to improve oral absorption and bioavailability of lipid soluble and highly permeable compounds. Thus, this study has focused on improving solubility in lipid excipients, controlling stability, and enhancing transmucosal permeability of SN38 by specific chemical modification. To achieve these aims, a series of lipophilic prodrugs were designed and synthesized by esterification at the C10 and/or C20 positon(s) of SN38 with dietary fatty acids of diverse hydrocarbon chain lengths. The solubility of these novel prodrugs in long-chain triglycerides was increased up to 444-fold, and cytotoxicity was significantly reduced in comparison to SN38. The prodrugs were stable in simulated gastric fluids but exhibited different rates of hydrolysis (t 1/2 < 5 min to t 1/2 > 2 h) in simulated intestinal fluids (in the presence of enzymes) depending on the alkyl chain length and the position modified. A predictable reconversion of prodrugs to SN38 in plasma was also confirmed. On the basis of these studies, SN38-undecanoate (C20) was identified as the optimal prodrug. Finally, in vitro permeability and uptake studies in rat intestinal mucosal membrane using an Ussing chamber showed significant improvement in transepithelial drug transport and cellular uptake. Together, these results indicate that well designed lipophilic prodrugs have potential for the efficacious and safe oral delivery of SN38. |
---|---|
AbstractList | SN38 (7-ethyl-10-hydroxy camptothecin) is a potent anticancer agent belonging to the camptothecin family; however, its oral delivery is extensively restricted by poor solubility in pharmaceutically acceptable excipients and low transmucosal permeability. Lipid-based carriers are well-known for their ability to improve oral absorption and bioavailability of lipid soluble and highly permeable compounds. Thus, this study has focused on improving solubility in lipid excipients, controlling stability, and enhancing transmucosal permeability of SN38 by specific chemical modification. To achieve these aims, a series of lipophilic prodrugs were designed and synthesized by esterification at the C10 and/or C20 positon(s) of SN38 with dietary fatty acids of diverse hydrocarbon chain lengths. The solubility of these novel prodrugs in long-chain triglycerides was increased up to 444-fold, and cytotoxicity was significantly reduced in comparison to SN38. The prodrugs were stable in simulated gastric fluids but exhibited different rates of hydrolysis (t 1/2 < 5 min to t 1/2 > 2 h) in simulated intestinal fluids (in the presence of enzymes) depending on the alkyl chain length and the position modified. A predictable reconversion of prodrugs to SN38 in plasma was also confirmed. On the basis of these studies, SN38-undecanoate (C20) was identified as the optimal prodrug. Finally, in vitro permeability and uptake studies in rat intestinal mucosal membrane using an Ussing chamber showed significant improvement in transepithelial drug transport and cellular uptake. Together, these results indicate that well designed lipophilic prodrugs have potential for the efficacious and safe oral delivery of SN38. SN38 (7-ethyl-10-hydroxy camptothecin) is a potent anticancer agent belonging to the camptothecin family; however, its oral delivery is extensively restricted by poor solubility in pharmaceutically acceptable excipients and low transmucosal permeability. Lipid-based carriers are well-known for their ability to improve oral absorption and bioavailability of lipid soluble and highly permeable compounds. Thus, this study has focused on improving solubility in lipid excipients, controlling stability, and enhancing transmucosal permeability of SN38 by specific chemical modification. To achieve these aims, a series of lipophilic prodrugs were designed and synthesized by esterification at the C10 and/or C20 positon(s) of SN38 with dietary fatty acids of diverse hydrocarbon chain lengths. The solubility of these novel prodrugs in long-chain triglycerides was increased up to 444-fold, and cytotoxicity was significantly reduced in comparison to SN38. The prodrugs were stable in simulated gastric fluids but exhibited different rates of hydrolysis (t1/2 < 5 min to t1/2 > 2 h) in simulated intestinal fluids (in the presence of enzymes) depending on the alkyl chain length and the position modified. A predictable reconversion of prodrugs to SN38 in plasma was also confirmed. On the basis of these studies, SN38-undecanoate (C20) was identified as the optimal prodrug. Finally, in vitro permeability and uptake studies in rat intestinal mucosal membrane using an Ussing chamber showed significant improvement in transepithelial drug transport and cellular uptake. Together, these results indicate that well designed lipophilic prodrugs have potential for the efficacious and safe oral delivery of SN38. |
Author | Wang, Shudong Bala, Vaskor Rao, Shasha Li, Peng Prestidge, Clive A |
AuthorAffiliation | School of Pharmacy and Medical Sciences University of South Australia |
AuthorAffiliation_xml | – name: School of Pharmacy and Medical Sciences – name: University of South Australia |
Author_xml | – sequence: 1 givenname: Vaskor surname: Bala fullname: Bala, Vaskor – sequence: 2 givenname: Shasha surname: Rao fullname: Rao, Shasha – sequence: 3 givenname: Peng surname: Li fullname: Li, Peng – sequence: 4 givenname: Shudong surname: Wang fullname: Wang, Shudong – sequence: 5 givenname: Clive A surname: Prestidge fullname: Prestidge, Clive A email: Clive.Prestidge@unisa.edu.au |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26623947$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkF1LwzAUhoNM3If-BYk_YDNJkzb1RmT4BcMJU--kpEnqMtqmJCkyf72d2wS92tU5cN73Pec8Q9Crba0BuMBoghHBl0L6SWXLZilcJaRuw4TlCCWcHYEBZjQa8yglvd-e0z4Yer9CiFBGohPQJ3FMopQmA_A-M41tlqY0Ej47q1z74aEt4OIp4ldwsa7DUnvjoagVNDV8M8FZOO0WCxm0M18iGFvDYD-FU3DuRNkNdWU7lxPN-hQcF6L0-mxXR-D17vZl-jCeze8fpzezsaAkDWPOEEcJponWRElEUsUojgslCh1zSQqkFOMc5ThWOMk3t0spE0G4jBIa5SIagfNtbtPmlVZZ40wl3Drb_9kJrrcC6az3TheZNOHn9uCEKTOMsg3ZrCOb_SGb7ch2Cem_hP2SQ7xs691IVrZ1dQfjAN83rj2Zeg |
CitedBy_id | crossref_primary_10_1016_j_ejps_2020_105340 crossref_primary_10_1039_C8BM00947C crossref_primary_10_1080_10601325_2023_2242409 crossref_primary_10_1016_j_jconrel_2018_07_022 crossref_primary_10_1021_acsbiomaterials_7b00023 crossref_primary_10_1016_j_phrs_2019_104398 crossref_primary_10_1016_j_colsurfb_2019_06_020 crossref_primary_10_1016_j_ijpharm_2023_122886 crossref_primary_10_1016_j_ajps_2024_100908 crossref_primary_10_1186_s12951_022_01257_4 crossref_primary_10_3390_molecules28134931 crossref_primary_10_36290_csf_2020_027 crossref_primary_10_1016_j_bmc_2017_04_025 crossref_primary_10_1007_s11095_021_03093_x crossref_primary_10_1021_acs_molpharmaceut_6b01027 crossref_primary_10_1007_s13346_021_00903_y crossref_primary_10_1038_s44222_023_00082_0 crossref_primary_10_1016_j_ejphar_2020_172937 crossref_primary_10_1111_jphp_12984 crossref_primary_10_1039_C8TB02319K crossref_primary_10_1016_j_ijpharm_2018_08_010 crossref_primary_10_1208_s12249_018_1272_0 crossref_primary_10_1016_j_ejmech_2019_06_009 crossref_primary_10_1016_j_jconrel_2020_10_036 crossref_primary_10_1016_j_colsurfb_2023_113736 crossref_primary_10_1021_acsbiomaterials_9b00689 crossref_primary_10_1021_acs_molpharmaceut_1c00761 crossref_primary_10_1007_s13346_018_0543_3 crossref_primary_10_1007_s13404_024_00346_6 crossref_primary_10_3389_fphar_2022_879660 crossref_primary_10_1007_s00894_023_05455_1 crossref_primary_10_1016_j_ejpb_2018_10_018 crossref_primary_10_1080_15421406_2020_1743447 crossref_primary_10_1002_med_21533 crossref_primary_10_1016_j_addr_2016_04_007 crossref_primary_10_1016_j_jconrel_2021_12_003 crossref_primary_10_3390_nu12041173 crossref_primary_10_4155_fmc_2019_0155 crossref_primary_10_1016_j_msec_2020_111332 crossref_primary_10_3390_pharmaceutics16121613 crossref_primary_10_1016_j_addr_2020_10_002 crossref_primary_10_1016_j_ijpharm_2021_120399 crossref_primary_10_1039_D4FO00906A crossref_primary_10_1021_acs_molpharmaceut_6b00591 crossref_primary_10_1016_j_ejmech_2019_04_074 crossref_primary_10_3390_molecules28093936 crossref_primary_10_3390_pharmaceutics11110569 crossref_primary_10_1007_s00280_018_3720_7 crossref_primary_10_1016_j_ijpharm_2019_118499 crossref_primary_10_1016_j_procbio_2020_09_010 crossref_primary_10_1039_C9TB01270B crossref_primary_10_1021_acs_bioconjchem_7b00774 crossref_primary_10_1080_21691401_2021_1907393 crossref_primary_10_1002_slct_201903035 |
Cites_doi | 10.1016/j.jconrel.2012.12.019 10.1016/j.jconrel.2013.07.022 10.1021/jm401644v 10.1146/annurev.bi.54.070185.003313 10.1016/j.ejpb.2014.12.014 10.1023/A:1018890106045 10.1016/j.jconrel.2013.12.031 10.3109/00498254.2011.646339 10.1002/9783527633166.ch4 10.1016/j.ecoenv.2010.03.006 10.1038/nrc1977 10.1021/jo000221n 10.1007/978-1-4614-0323-4_9 10.1016/j.jconrel.2014.12.030 10.1152/ajpgi.90649.2008 10.1021/cr0780210 10.1158/1078-0432.CCR-1585-3 10.1023/A:1012148300807 10.1111/j.1749-6632.2000.tb07031.x 10.1124/jpet.103.052522 10.1016/S0090-9556(24)15060-X 10.1158/1535-7163.TARG-09-C218 10.1038/nrd2197 10.1021/cr900097c 10.1016/j.jconrel.2010.11.022 10.1111/j.1749-6632.2000.tb07040.x 10.1038/sj.bjc.6600591 10.1016/j.addr.2011.05.019 10.1002/pbc.25105 10.1021/bc100094z 10.1038/84635 10.2174/1389200033489253 10.1016/j.addr.2007.10.014 10.1016/j.ejps.2012.10.007 10.1016/j.ejpb.2011.01.021 10.1021/bc700333s 10.1021/jm9607562 10.1200/JCO.2008.20.6300 10.1200/JCO.2000.18.3.659 10.1097/CAD.0b013e32835c3543 10.1002/anie.197805221 10.1021/jm0309957 10.1002/1520-6017(200008)89:8<1073::AID-JPS12>3.0.CO;2-V 10.1038/35077241 10.1088/0957-4484/24/24/245101 |
ContentType | Journal Article |
Copyright | Copyright © 2015 American Chemical Society |
Copyright_xml | – notice: Copyright © 2015 American Chemical Society |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM |
DOI | 10.1021/acs.molpharmaceut.5b00785 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1543-8392 |
EndPage | 294 |
ExternalDocumentID | 26623947 10_1021_acs_molpharmaceut_5b00785 b46531779 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - 123 53G 55A 7~N AABXI ABMVS ABUCX ACGFS ACS AEESW AENEX AFEFF ALMA_UNASSIGNED_HOLDINGS AQSVZ CS3 DU5 EBS ED ED~ EJD F5P GNL H~9 IH9 JG JG~ P2P RNS ROL UI2 VF5 VG9 W1F X --- -~X 4.4 5VS AAYXX ABBLG ABJNI ABLBI ABQRX ADHLV AHGAQ BAANH CITATION CUPRZ GGK CGR CUY CVF ECM EIF NPM |
ID | FETCH-LOGICAL-a429t-850807147ee2dc029d5416fdafe68c2f0dd5880b16d17b6623ccc7a28c3743ba3 |
IEDL.DBID | ACS |
ISSN | 1543-8384 |
IngestDate | Thu Jan 02 22:24:03 EST 2025 Thu Apr 24 22:59:20 EDT 2025 Wed Oct 01 06:02:37 EDT 2025 Thu Aug 27 13:42:32 EDT 2020 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | drug delivery simulated gastric/intestinal conditions lipophilic prodrug cytotoxicity SN38 (7-ethyl-10-hydorxy camptothecin) permeability |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a429t-850807147ee2dc029d5416fdafe68c2f0dd5880b16d17b6623ccc7a28c3743ba3 |
PMID | 26623947 |
PageCount | 8 |
ParticipantIDs | pubmed_primary_26623947 crossref_citationtrail_10_1021_acs_molpharmaceut_5b00785 crossref_primary_10_1021_acs_molpharmaceut_5b00785 acs_journals_10_1021_acs_molpharmaceut_5b00785 |
ProviderPackageCode | JG~ 55A AABXI GNL VF5 7~N VG9 W1F ACS AEESW AFEFF ABMVS ABUCX IH9 AQSVZ ED~ UI2 CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-01-04 |
PublicationDateYYYYMMDD | 2016-01-04 |
PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-04 day: 04 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular pharmaceutics |
PublicationTitleAlternate | Mol. Pharmaceutics |
PublicationYear | 2016 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | ref45/cit45 ref27/cit27 ref16/cit16 ref23/cit23 ref31/cit31 ref2/cit2 ref34/cit34 Moridani M. Y. (ref20/cit20) 2010 ref37/cit37 Sparreboom A. (ref10/cit10) 1998; 4 ref17/cit17 ref35/cit35 ref19/cit19 ref21/cit21 ref42/cit42 ref46/cit46 ref49/cit49 Marchand C. (ref3/cit3) 2012 ref13/cit13 ref24/cit24 ref38/cit38 Lundberg B. (ref48/cit48) 1998; 13 ref50/cit50 ref6/cit6 ref36/cit36 Mathijssen R. H. J. (ref8/cit8) 2001; 7 ref18/cit18 ref11/cit11 ref25/cit25 ref29/cit29 Slatter J. G. (ref9/cit9) 2000; 28 ref32/cit32 ref39/cit39 ref14/cit14 ref5/cit5 ref51/cit51 ref43/cit43 ref28/cit28 ref40/cit40 ref26/cit26 ref12/cit12 ref15/cit15 Takimoto C. H. (ref44/cit44) 2000; 18 ref41/cit41 ref22/cit22 ref33/cit33 ref4/cit4 ref30/cit30 ref47/cit47 ref1/cit1 ref7/cit7 |
References_xml | – ident: ref42/cit42 doi: 10.1016/j.jconrel.2012.12.019 – ident: ref12/cit12 doi: 10.1016/j.jconrel.2013.07.022 – ident: ref43/cit43 doi: 10.1021/jm401644v – ident: ref1/cit1 doi: 10.1146/annurev.bi.54.070185.003313 – ident: ref35/cit35 doi: 10.1016/j.ejpb.2014.12.014 – ident: ref33/cit33 doi: 10.1023/A:1018890106045 – ident: ref27/cit27 doi: 10.1016/j.jconrel.2013.12.031 – ident: ref49/cit49 doi: 10.3109/00498254.2011.646339 – volume: 7 start-page: 2182 issue: 8 year: 2001 ident: ref8/cit8 publication-title: Clin. Cancer Res. – start-page: 79 volume-title: Prodrugs and Targeted Delivery year: 2010 ident: ref20/cit20 doi: 10.1002/9783527633166.ch4 – ident: ref30/cit30 doi: 10.1016/j.ecoenv.2010.03.006 – ident: ref2/cit2 doi: 10.1038/nrc1977 – ident: ref39/cit39 doi: 10.1021/jo000221n – start-page: 175 volume-title: DNA Topoisomerases and Cancer year: 2012 ident: ref3/cit3 doi: 10.1007/978-1-4614-0323-4_9 – ident: ref23/cit23 doi: 10.1016/j.jconrel.2014.12.030 – ident: ref32/cit32 doi: 10.1152/ajpgi.90649.2008 – volume: 13 start-page: 453 issue: 5 year: 1998 ident: ref48/cit48 publication-title: Anticancer Drug Des. – ident: ref5/cit5 doi: 10.1021/cr0780210 – ident: ref45/cit45 doi: 10.1158/1078-0432.CCR-1585-3 – ident: ref47/cit47 doi: 10.1023/A:1012148300807 – ident: ref37/cit37 doi: 10.1111/j.1749-6632.2000.tb07031.x – ident: ref21/cit21 doi: 10.1124/jpet.103.052522 – volume: 28 start-page: 423 issue: 4 year: 2000 ident: ref9/cit9 publication-title: Drug Metab. Dispos. doi: 10.1016/S0090-9556(24)15060-X – ident: ref17/cit17 doi: 10.1158/1535-7163.TARG-09-C218 – ident: ref22/cit22 doi: 10.1038/nrd2197 – volume: 4 start-page: 2747 issue: 11 year: 1998 ident: ref10/cit10 publication-title: Clin. Cancer Res. – ident: ref4/cit4 doi: 10.1021/cr900097c – ident: ref15/cit15 doi: 10.1016/j.jconrel.2010.11.022 – ident: ref36/cit36 doi: 10.1111/j.1749-6632.2000.tb07040.x – ident: ref13/cit13 doi: 10.1038/sj.bjc.6600591 – ident: ref25/cit25 doi: 10.1016/j.addr.2011.05.019 – ident: ref41/cit41 doi: 10.1002/pbc.25105 – ident: ref14/cit14 doi: 10.1021/bc100094z – ident: ref18/cit18 – ident: ref50/cit50 doi: 10.1038/84635 – ident: ref34/cit34 – ident: ref19/cit19 doi: 10.2174/1389200033489253 – ident: ref24/cit24 doi: 10.1016/j.addr.2007.10.014 – ident: ref46/cit46 doi: 10.1016/j.ejps.2012.10.007 – ident: ref16/cit16 doi: 10.1016/j.ejpb.2011.01.021 – ident: ref29/cit29 doi: 10.1021/bc700333s – ident: ref38/cit38 doi: 10.1021/jm9607562 – ident: ref11/cit11 doi: 10.1200/JCO.2008.20.6300 – volume: 18 start-page: 659 issue: 3 year: 2000 ident: ref44/cit44 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2000.18.3.659 – ident: ref40/cit40 doi: 10.1097/CAD.0b013e32835c3543 – ident: ref28/cit28 doi: 10.1002/anie.197805221 – ident: ref31/cit31 doi: 10.1021/jm0309957 – ident: ref7/cit7 – ident: ref26/cit26 doi: 10.1002/1520-6017(200008)89:8<1073::AID-JPS12>3.0.CO;2-V – ident: ref51/cit51 doi: 10.1038/35077241 – ident: ref6/cit6 doi: 10.1088/0957-4484/24/24/245101 |
SSID | ssj0024523 |
Score | 2.3852782 |
Snippet | SN38 (7-ethyl-10-hydroxy camptothecin) is a potent anticancer agent belonging to the camptothecin family; however, its oral delivery is extensively restricted... |
SourceID | pubmed crossref acs |
SourceType | Index Database Enrichment Source Publisher |
StartPage | 287 |
SubjectTerms | Camptothecin - analogs & derivatives Camptothecin - chemistry Cell Survival - drug effects Drug Delivery Systems - methods HCT116 Cells Humans Prodrugs - adverse effects Prodrugs - chemical synthesis Prodrugs - chemistry Tandem Mass Spectrometry |
Title | Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy |
URI | http://dx.doi.org/10.1021/acs.molpharmaceut.5b00785 https://www.ncbi.nlm.nih.gov/pubmed/26623947 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVABC databaseName: American Chemical Society Journals customDbUrl: eissn: 1543-8392 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024523 issn: 1543-8384 databaseCode: ACS dateStart: 20040101 isFulltext: true titleUrlDefault: https://pubs.acs.org/action/showPublications?display=journals providerName: American Chemical Society |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bS8MwFA5eQHzxfpk3Isie1tmmSZv6JsMh4mWwTfYiJbfKUNuxdg_z15u03cb0we219JQkPT3n60m-7wBwFXBEuIOZhR2kLBw42OK2p6xICtfnkWnFbfjOT8_efRc_9EhvxuP-vYOPnGsm0vpXYoinZYm3TrhJbGQVrCOPOuaP67bRngnskbynm4YGrkVdijfA5b-PMqlJpHOpaQ5k5smmuQ06E8pOccbkoz7KeF18_1VwXGYeO2CrBJ_wtvCWXbCi4j1QbRX3jmuwMyNjpTVYha2ZrvV4H7w99gfJwBRgBGzpuDscvacwiWD72aU3sD2ONZZM-ylksYT9GL72s2ECG1NB6ILvCbP8nC58GeqBGLWCkgE2PgDd5l2ncW-V3RkspnNYZlEN7Qz7yVcKSWGjQBIN7iLJIuVRgSJbSqKDA3c86fjc0zBLCOEzRLUTYJcz9xCsxUmsjgGUigbUo7bUwQBLghhzkR95hNnMqNWICtDOlYbl15WG-cY5ckJzcW5Jw3JJK4BO3mQoSq1z03LjcxFTNDUdFIIfixgdFe4yNUFmwgH2T5Yd-inY1JisqPLgM7CWDUfqXOOejF_kfv4Dg94DXw |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1dT9swFL0aIAEv43NbxwZGQjyRkjh24uxtqoYKlFKpBSEhFPkrqIIlVZM-dL9-dpK1Ki8DXq1c69q-8T2yfc4FOIoEpsIj3CEe1g6JPOIIN9BOoqQfisSW4rZ856tu0L4hF3f0rn5Vabkwxonc9JSXl_hzdQHv1Lb9ziz_tD7pbVJh8xtdgpVSEcXColZ_rrNHy9JuBiH4DvMZWYXD_3ZlM5TMFzLUAtYsc87ZBtzPvC2fmjw1J4Voyj8vhBzfN5xN-FhDUfSzip0t-KDTbTjuVd9OT9BgTs3KT9Ax6s1Vrqc78NAZjrKRPY6RqGd24fHkMUdZgvpdn_1A_WlqkGU-zBFPFRqm6HZYjDPUmslDV-xPVJSvdtH12DhitQtqPth0F27Ofg1abaeu1eBwk9EKhxmgZ7lQodZYSRdHihqolyie6IBJnLhKUbNVCC9QXigCA7qklCHHzIQE8QX3P8FymqX6CyClWcQC5iqzNRBFMec-DpOAcpdb7RrZADujcf2v5XF5jY692DYuTGlcT2kD2L8FjWWtfG4LcDy_xhTPTEeV_MdrjD5XUTMzwXbAEQm_vtX1A1hrD646cee8e7kH6watVec_5BssF-OJ_m4QUSH2y9D_C6MjC8o |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NTZp4YYyPMTaGkdCeli5x7MTZGypUA0ap1A3tBUX-ylQBSdWkD-Wvx5eYVuVlY69Wzjo757ufzr7fAbzNFOUqYjJgEbUByyIWqDCxQWF0nKoCW3FjvfOXYXJ-xT5d82ufcMNaGKdE7Waq20t8PNVTU3iGgegUx39VWIPqs709rjDG8QewxZEKDqFRf7zi2uNtezeHEuJAxIJtw5tbp8Iopeu1KLWGN9u4M9iBfKlx-9zkR2_eqJ7-_Q-Z4_2X9BgeeUhK3nU2tAsbtnwCx6Pu28UJuVyVaNUn5JiMVmzXi6fw_WIyraaYltFk5LzxbH5Tk6og42Eszsh4UTqEWU9qIktDJiX5NmlmFekvaaK7KlDStK93ydeZUwQ5DHxd2OIZXA0-XPbPA9-zIZAusjWBcIAPa6JSa6nRIc0Md5CvMLKwidC0CI3hzmWoKDFRqhIHvrTWqaTCmQaLlYyfw2ZZlfYFEGNFJhIRGucimOFUypimRcJlKJHDRu8D7mruz1ydt9fpNMpxcG1Lc7-l-yD-_tRcewZ0bMTx8y6idCk67WhA7iK011nOUoTigjOWvvxf1V_D9uj9IL_4OPx8AA8daOvSQOwQNpvZ3L5ywKhRR631_wEBJw5E |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lipophilic+Prodrugs+of+SN38%3A+Synthesis+and+in+Vitro+Characterization+toward+Oral+Chemotherapy&rft.jtitle=Molecular+pharmaceutics&rft.au=Bala%2C+Vaskor&rft.au=Rao%2C+Shasha&rft.au=Li%2C+Peng&rft.au=Wang%2C+Shudong&rft.date=2016-01-04&rft.pub=American+Chemical+Society&rft.issn=1543-8384&rft.eissn=1543-8392&rft.volume=13&rft.issue=1&rft.spage=287&rft.epage=294&rft_id=info:doi/10.1021%2Facs.molpharmaceut.5b00785&rft.externalDocID=b46531779 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon |